Accessibility StatementSkip Navigation Following the positive interim results in 5 patients announced earlier this year, a total of 9 patients have been enrolled as planned The study is progressing according to protocol, and no safety issues have been reported Study completion is anticipated in Q4 2025 with topline to follow HOUSTON, Sept. 29, 2025 /PRNewswire/ -- Coya Therapeutics, Inc. (NASDAQ: COYA) ("Coya" or the "Company"), a clinical-stage biotechnology company focused on developing biologics that enh ...

Accessibility StatementSkip Navigation Highlights of the REZOLVE-AD Phase 2b Study: Week 16 Efficacy | 24 µg/kg q2w | 18 µg/kg q2w | 24 µg/kg q4w | Placebo | | | | --- | --- | --- | --- | --- | --- | | (high dose) | (middle dose) | (low dose) | | | | | Primary Endpoint | N=104 | N=106 | N=110 | N=73 | | | Mean improvement inEASI score frombaseline | 61% | 58% | 53% | 31Â | % | | | p<0.001 | p<0.001 | p<0.001 | | | | Key SecondaryEndpoints | N=73 | N=104 | N=106 | N=110 | | | | 42% | 46% | 34% | | | | EASI-7 ...

Nektar Therapeutics (NasdaqCM:NKTR) FY Conference September 10, 2025 10:30 AM ET Speaker0Get started. Good morning, everyone. Thanks for joining us today. My name is Arthur He, a senior biotech analyst at the HC Wainwright. Thanks for joining us to have a conversation with doctor Jonathan Zalevsky, chief r and d officer.A little bit about Nektar. Nektar is a global biopharmaceutical company focused on developing novel therapies that selectively moderate the immune system to treat autoimmune disorder by leve ...